These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J. J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270 [Abstract] [Full Text] [Related]
7. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G. Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748 [Abstract] [Full Text] [Related]
8. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease. Cantarovich F, Rangoonwala B. Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572 [Abstract] [Full Text] [Related]
11. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G. Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975 [Abstract] [Full Text] [Related]
13. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. Weir MR. J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800 [Abstract] [Full Text] [Related]
14. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H. Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684 [Abstract] [Full Text] [Related]
15. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866 [Abstract] [Full Text] [Related]
16. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Arici M, Erdem Y. Am J Kidney Dis; 2009 Feb; 53(2):332-45. PubMed ID: 19166800 [Abstract] [Full Text] [Related]
17. Blocking the renin-angiotensin system: dual- versus mono-therapy. Ravandi A, Teo KK. Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282 [Abstract] [Full Text] [Related]
18. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U, Chaisuvannarat V. J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [Abstract] [Full Text] [Related]
19. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y. Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123 [Abstract] [Full Text] [Related]
20. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy]. Fronczyk A, Majkowska L. Przegl Lek; 2007 May; 64(2):81-5. PubMed ID: 17892038 [Abstract] [Full Text] [Related] Page: [Next] [New Search]